COMMUNIQUÉS West-GlobeNewswire
-
Matisse Pharmaceuticals receives FDA IND clearance for isupartob sodium
19/05/2026 -
EyePoint Announces Participation at Upcoming Investor Conferences
19/05/2026 -
XORTX Announces Closing of US$5 Million Public Offering
19/05/2026 -
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
19/05/2026 -
Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy
19/05/2026 -
Leo International Precision Health AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
19/05/2026 -
Medicenna Announces the Finalization of the Terms of its Public Offering of Securities
19/05/2026 -
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
19/05/2026 -
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
19/05/2026 -
ITM to Announce Dosimetry Data from the Phase 3 COMPETE Trial at SNMMI 2026 and Host Satellite Symposium
19/05/2026 -
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology
19/05/2026 -
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
19/05/2026 -
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
19/05/2026 -
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
19/05/2026 -
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
19/05/2026 -
Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance, Outperforming Industry Benchmarks
19/05/2026 -
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
19/05/2026 -
Risen Pharma Announces Initiation of Phase 2 Clinical Trial of RP902 for Mild Cognitive Impairment Due to Alzheimer’s Disease
19/05/2026 -
Vanqua Bio to Present Positive Biomarker Data from Ongoing Phase 1b Study at Upcoming Medical Conferences
19/05/2026
Pages